Serum Galectin-3 Predicts Mortality in Venoarterial Extracorporeal Membrane Oxygenation Patients

Objective. We investigated the potential use of galectin-3 (Gal-3) as a prognostic indicator for patients with cardiogenic shock and developed a predictive mortality model for venoarterial extracorporeal membrane oxygenation (VA-ECMO). Methods. We prospectively studied patients (survivors and nonsur...

Full description

Saved in:
Bibliographic Details
Published in:Cardiology research and practice 2023-09, Vol.2023, p.1-8
Main Authors: Zhu, Jianlong, Guo, Dehui, Liu, Liying, Zhong, Jing
Format: Article
Language:English
Subjects:
Analysis
Blood pressure
Body mass index
Cardiac function
Cardiomyopathy
Cardiovascular disease
Extracorporeal membrane oxygenation
Heart attacks
Hypertension
Hypotension
Medical research
Medicine, Experimental
Mortality
Myocarditis
Natriuretic peptides
Normal distribution
Patient outcomes
Patients
Physiological aspects
Prognosis
Shock
Statistical analysis
Surgery
Taiwan
Type 2 diabetes
Ultrasonic imaging
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. We investigated the potential use of galectin-3 (Gal-3) as a prognostic indicator for patients with cardiogenic shock and developed a predictive mortality model for venoarterial extracorporeal membrane oxygenation (VA-ECMO). Methods. We prospectively studied patients (survivors and nonsurvivors) who received VA-ECMO for cardiogenic shock from 2019 to 2021. We recorded baseline data, Gal-3, and B-type natriuretic peptide (BNP) before ECMO and 24–72 h after ECMO. We used multivariable logistic regression to analyze significant risk factors and construct a VA-ECMO death prediction model. Receiver operating characteristic (ROC) curves were plotted to assess the predictive efficacy of the model. Results. We enrolled 73 patients with cardiogenic shock who received VA-ECMO support; 38 (52.05%) died in hospital. The median age was 57 years (interquartile range (IQR): 48–67 years); the median duration of ECMO therapy was 5.8 days (IQR: 4.62–7.57 days); and the median intensive care unit stay was 19.04 days (IQR: 13.92–26.15 days). Compared with the nonsurvivors, survivors had lower acute physiology and chronic health evaluation (APACHE) II scores (p 
ISSN:2090-8016
2090-0597
2090-0597
DOI:10.1155/2023/3917156